| 证券代码 | MYOK.O |
| 证券名称 | MyoKardia Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-10-29 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 5437500 |
| 首发募资额(元) | 54,375,000.00 USD |
| 首发主承销商 | Cowen and Company, LLC,Credit Suisse Securities (USA) LLC |
| 货币单位 | USD |
| 公司名称 | MyoKardia, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 333 Allerton Avenue, South San Francisco, California, USA |
| 成立日期 | 2012-06 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.myokardia.com |
| 电话 | +1 (650) 741-0900 |
| 传真 | - |
| 公司简介 | MyoKardia, Inc. , incorporated under the laws of the State of Delaware in 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It has used its precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. It has generated several proprietary, orally administered small molecules to address a variety of biomechanical defects that cause disruptions in heart muscle contraction. By correcting the underlying biomechanical defects, it believe its targeted therapies can correct or offset the downstream disruption in cardiac muscle function that drives disease progression. |